

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1061)

**SUPPLEMENTAL ANNOUNCEMENT RELATING TO
DISCLOSEABLE TRANSACTION**

**PRODUCT INTERESTS TRANSFER AGREEMENT RELATING TO
IODIZED LECITHIN CAPSULES* (適麗順)**

Reference is made to the announcement of Essex Bio-Technology Limited (the “**Company**”) dated 9 June 2021 in relation to the Possible Acquisition by the Group of the Target Assets relating to the Product (i.e. Iodized Lecithin Capsules* (適麗順)) (the “**Announcement**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as defined in the Announcement.

This announcement is to provide supplemental information on the Target Assets and the Option (as defined below).

INFORMATION ON THE TARGET ASSETS

As disclosed in the Announcement, the Target Assets (which were held by Parkson Pharmaceutical and other relevant parties before the Possible Acquisition) consist of technologies, process, trademarks, patent and other rights relating to the Product.

Based on the information provided by Parkson Pharmaceutical, during the preceding two financial years before the Possible Acquisition, (i) the Target Assets were not finished goods ready for trade or sale but were used for the production of the Product; and (ii) certain technologies and/or process which formed part of the Target Assets were also used, in conjunction with other intellectual property rights held by Parkson Pharmaceutical and/or other relevant parties for the production of pharmaceutical products other than the Product.

Given the highly specialised, technical and intangible nature of the Target Assets and that the Target Assets were held by multiple owners and were used together with other components and cost items in the production of different pharmaceutical products, distinctive revenue or expenses cannot be attributable to the Target Assets and no identifiable income stream can be assigned to the Target Assets.

THE OPTION

As disclosed in the Announcement, Zhuhai Essex has the right to request Parkson Pharmaceutical to buyback the Target Assets if the Product is unable to obtain the relevant approval for sale due to the rules and regulations of the national drugs registration during the period falling within 10 years from the date of the Framework Agreement (the “**Option**”). In exercising the Option, the Company will observe and comply with the relevant requirements under Rules 14.73, 14.75 and 14.77 of the Listing Rules, as and when appropriate.

On behalf of the Board
Essex Bio-Technology Limited
Ngiam Mia Je Patrick
Chairman

Hong Kong, 30 August 2021

Executive directors of the Company as at the date of this announcement are Mr. Ngiam Mia Je Patrick, Mr. Fang Haizhou, Mr. Ngiam Hian Leng Malcolm and Ms. Yau Lai Man. Independent non-executive directors of the Company as at the date of this announcement are Mr. Fung Chi Ying, Mr. Mauffrey Benoit Jean Marie and Ms. Yeow Mee Mooi.

* *For identification purpose only*